New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 6, 2012
08:08 EDTINFIInfinity Pharmaceuticals sees FY12 revenue $47.1M, consensus $113.91M
Infinity expects FY12 total revenue $47.1M composed of $45.0M for reimbursed R&D services from Mundipharma and $2.1M due to the amortization of deferred revenue. Infinity does not expect to recognize any revenue in future periods from the previous strategic alliance with Purdue and Mundipharma. Infinity expects FY12 operating expenses $125M-$135M revised from an earlier expectation of $135M-$145M. Infinity expects FY12 net loss $35M-$45M. Cash and investments: Infinity expects to end 2012 with a year-end cash and investments balance ranging from $155M-$165M, revised from an earlier expectation of $65M-$75M.
News For INFI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 9, 2014
11:31 EDTINFIInfinity Pharmaceuticals reports results from Phase 1 study of duvelisib
Infinity Pharmaceuticals reported updated data from a Phase 1 monotherapy study of duvelisib, an inhibitor of phosphoinositide-3-kinase-delta and PI3K-gamma, which showed activity among patients with relapsed/refractory indolent non-Hodgkin lymphoma, a fatal type of blood cancer. In the study, duvelisib demonstrated an overall response rate of 72%, including a 33% complete response rate, among 18 patients with iNHL who received the dose administered in ongoing registration-focused studies. In a separate presentation, updated Phase 1 data were also reported showing the activity of duvelisib in patients with relapsed/refractory T-cell lymphoma.
December 8, 2014
10:47 EDTINFIInfinity reports updated Phase 1 data from duvelisib study, says well tolerated
Subscribe for More Information
December 7, 2014
14:31 EDTINFIInfinity Pharmaceuticals to hold a luncheon and data presentation meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use